# US 2026/0063647 A1 · Combinations of biomarkers for methods for detecting trisomy 21

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0063647 A1
- Document ID: US20260063647A1
- Status: Published application
- Kind: A1
- Application number: 19/388,492
- Filed: 2025-11-13
- Published: 2026-03-05
- Earliest claimed: 2021-03-16
- Assignees: Rosetta Signaling Laboratories, LLC
- Applicants: Rosetta Signaling Laboratories, LLC
- Inventors: Carl Philip Weiner; Yafeng Dong
- Web page: https://patentgrep.com/patent/US20260063647A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2800/387: Down syndrome; Trisomy 18; Trisomy 13
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for detecting a Group of Biomarkers is provided herein. The translation profile of the Group of Biomarkers can be used for determining whether a subject, such as a fetus, has Down syndrome The methods include detecting one or more specific groups of biomarkers in a biological sample, and determining whether the expression of the biomarkers is altered when compared to expression of the biomarkers in one or more subjects that do not have trisomy 21 (e.g., a transcriptional standard). The biological sample can be a blood sample, and the biomarkers are cell free plasma RNAs.

## Claims

### Claim 1

A method of detecting a combination of ribonucleic acid (RNA) biomarkers, the method comprising:
obtaining a plasma sample from a human subject, wherein the human subject is a pregnant female;
obtaining cell free nucleic acids from the plasma sample, wherein the cell free nucleic acids are cell free ribonucleic acids (RNA);
detecting in the cell free RNA the presence of the combination of RNA biomarkers,
wherein the detecting comprises:
contacting the cell free RNA with a combination of primers or probes that are complementary to the combination of RNA biomarkers, and
detecting hybridization between the primers or probes and the combination of RNA biomarkers,
wherein the combination of RNA biomarkers used in the method consists of:
RASGRP4, hsa-mir-26b, UBASH3A, NCAM2, COL6A1, and ISOSLG.

### Claim 2 (depends on 1)

The method of claim 1, further comprising detecting a normalization nucleic acid.

### Claim 3 (depends on 1)

The method of claim 1, further comprising:
obtaining a plasma sample from a second human subject, wherein the second human subject is a pregnant female carrying a fetus without trisomy 21;
obtaining a second cell free ribonucleic acid sample from the plasma sample; and
detecting in the second cell free ribonucleic acid sample the presence of the combination of RNA biomarkers.

### Claim 4 (depends on 3)

The method of claim 3, further comprising:
quantitating the amount of each RNA biomarker in the cell free RNA from the pregnant female; and
quantitating the amount of each RNA biomarker in the second cell free ribonucleic acid sample from the second pregnant female.

### Claim 5

A method of detecting a combination of ribonucleic acid (RNA) biomarkers, the method comprising:
obtaining a plasma sample from a human subject, wherein the human subject is a pregnant female;
obtaining cell free nucleic acids from the plasma sample, wherein the cell free nucleic acids are cell free ribonucleic acids (RNA);
detecting in the cell free RNA the presence of the combination of RNA biomarkers,
wherein the detecting comprises:
contacting the cell free RNA with a combination of primers or probes that are complementary to the combination of RNA biomarkers, and
detecting hybridization between the primers or probes and the combination of RNA biomarkers,
wherein the combination of RNA biomarkers used in the method consists of:
GART, hsa-mir-26b, hsa-mir-450b, COL6A1, ATP50, ENSG00000199633 F2, and DOP1B.

### Claim 6 (depends on 5)

The method of claim 5, further comprising detecting a normalization nucleic acid.

### Claim 7 (depends on 5)

The method of claim 5, further comprising:
obtaining a plasma sample from a second human subject, wherein the second human subject is a pregnant female carrying a fetus without trisomy 21;
obtaining a second cell free ribonucleic acid sample from the plasma sample; and
detecting in the second cell free ribonucleic acid sample the presence of the combination of RNA biomarkers.

### Claim 8 (depends on 7)

The method of claim 7, further comprising:
quantitating the amount of each RNA biomarker in the cell free RNA from the pregnant female; and
quantitating the amount of each RNA biomarker in the second cell free ribonucleic acid sample from the second pregnant female.

### Claim 9

A method of detecting a combination of ribonucleic acid (RNA) biomarkers, the method comprising:
obtaining a plasma sample from a human subject, wherein the human subject is a pregnant female;
obtaining cell free nucleic acids from the plasma sample, wherein the cell free nucleic acids are cell free ribonucleic acids (RNA);
detecting in the cell free RNA the presence of the combination of RNA biomarkers,
wherein the detecting comprises:
contacting the cell free RNA with a combination of primers or probes that are complementary to the combination of RNA biomarkers, and
detecting hybridization between the primers or probes and the combination of RNA biomarkers,
wherein the combination of RNA biomarkers used in the method consists of:
hsa-mir-26b, RASGRP4, ICOSLG, UBASH3A, DOP1B, and FAM20A.

### Claim 10 (depends on 9)

The method of claim 9, further comprising detecting a normalization nucleic acid.

### Claim 11 (depends on 9)

The method of claim 9, further comprising:
obtaining a plasma sample from a second human subject, wherein the second human subject is a pregnant female carrying a fetus without trisomy 21;
obtaining a second cell free ribonucleic acid sample from the plasma sample; and
detecting in the second cell free ribonucleic acid sample the presence of the combination of RNA biomarkers.

### Claim 12 (depends on 11)

The method of claim 11, further comprising:
quantitating the amount of each RNA biomarker in the cell free RNA from the pregnant female; and
quantitating the amount of each RNA biomarker in the second cell free ribonucleic acid sample from the second pregnant female.

### Claim 13

A method of detecting a combination of ribonucleic acid (RNA) biomarkers, the method comprising:
obtaining a plasma sample from a human subject, wherein the human subject is a pregnant female;
obtaining cell free nucleic acids from the plasma sample, wherein the cell free nucleic acids are cell free ribonucleic acids (RNA);
detecting in the cell free RNA the presence of the combination of RNA biomarkers,
wherein the detecting comprises:
contacting the cell free RNA with a combination of primers or probes that are complementary to the combination of RNA biomarkers, and
detecting hybridization between the primers or probes and the combination of RNA biomarkers,
wherein the combination of RNA biomarkers used in the method consists of:
hsa-mir-26b, RASGRP4, NCAM2, ENSG00000207147 F2, UBASH3A, and ENSG00000199856 F1.

### Claim 14 (depends on 13)

The method of claim 13, further comprising detecting a normalization nucleic acid.

### Claim 15 (depends on 13)

The method of claim 13, further comprising:
obtaining a plasma sample from a second human subject, wherein the second human subject is a pregnant female carrying a fetus without trisomy 21;
obtaining a second cell free ribonucleic acid sample from the plasma sample; and
detecting in the second cell free ribonucleic acid sample the presence of the combination of RNA biomarkers.

### Claim 16 (depends on 15)

The method of claim 15, further comprising:
quantitating the amount of each RNA biomarker in the cell free RNA from the pregnant female; and
quantitating the amount of each RNA biomarker in the second cell free ribonucleic acid sample from the second pregnant female.
